HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virus-specific immunoglobulin G after vaccination and infection

Journal of Infectious Diseases

Volumn 200, Issue 7, 2009, Pages 1031-1038

  Nair, Nitya ^a   Moss, William J ^a   Scott, Susana ^d   Mugala, Nanthalile ^e   Ndhlovu, Zaza M ^a   Lilo, Kareem ^a   Ryon, Judith J ^a   Monze, Mwaka ^e   Quinn, Thomas C ^b,c   Cousens, Simon ^d   Cutts, Felicity ^d   Griffin, Diane E ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY TEACHING HOSPITAL   (Zambia)

Author keywords

[No Author keywords available]

Indexed keywords

CD150 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; MEASLES ANTIBODY; MEASLES VACCINE;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; MALE; MEASLES; MEASLES VACCINATION; MEASLES VIRUS; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; VERO CELL; VIRUS NEUTRALIZATION; VIRUS PLAQUE; VIRUS STRAIN; WILD TYPE; ZAMBIA;

ANTIBODIES, VIRAL; ANTIBODY AFFINITY; CHILD, PRESCHOOL; ENDEMIC DISEASES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; INFANT; MALE; MEASLES; MEASLES VACCINE; MEASLES VIRUS; TIME FACTORS; VACCINATION; ZAMBIA;

EID: 70349321516     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/605648     Document Type: Article

References (45)

1. Wolf'son LJ, Strebel PM, Gacic-Dobo M, Hoekstra EJ, McFarland JW, Hersh BS. Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 2007; 369:191-200.
2. Cutts FT, Henao-Restrepo A, Olive JM. Measles elimination: progress and challenges. Vaccine 1999;17(Suppl 3):S47-52.
3. Moss WJ, Cutts F, Griffin DE. Implications of the HIV epidemic for control and eradication of measles. Clin Infect Dis 1999;29:106-112
4. Scott S, Moss WJ, Cousens S, et al. The influence of HIV-1 exposure and infection on levels of 'passively acquired antibodies to measles virus in Zambian infants. Clin Infect Dis 2007;45:1417-1424
5. Centers for Disease Control. Measles in HIV-infected children, United States. MMWR Morb Mortal Wkly Rep 1988;37:183-186
6. Moss WJ, Fisher C, Scott S, et al. HIV type 1 infection is a risk factor for mortality in hospitalized Zambian children with measles. Clin Infect Dis 2008;46:523-527 (Pubitemid 351263489)
7. Permar SR, Moss WJ, Ryon JJ, et al. Prolonged measles virus shedding in human immunodeficiency virus-infected children, detected by re- verse transcriptase-polymerase chain reaction. J Infect Dis 2001; 183: 532-538
8. Scott S, Mossong J, Moss WJ, Cutts FT, Cousens S. Predicted impact of the HIV-1 epidemic on measles in developing countries: results from a dynamic age-structured model. Int J Epidemiol 2008;37:356-367
9. ChenRT,MarkowitzLE,AlbrechtP,etal.Measlesantibody: reevaluationofprotectivetiters.JInfectDis1990;162:1036-1042(Pubitemid20353580)
10. Moss WJ, Scott S, Mugala N, et al. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study. J Infect Dis 2007; 196:347-355 (Pubitemid 47093884)
11. Helfand RF, Witte D, Fowlkes A, et al. Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi. J Infect Dis 2008; 198:1457-1465
12. Brunell PA, Vimal V, Sandu M, Courville TM, Daar E, Israele V. Abnormalities of measles antibody response in human immunodeficiency virus type 1 (HIV-1) infection. J Acquir Immune Defic Syndr Hum Retroviral 1995; 10:540-548
13. Hashiguchi T, Kajikawa M., Maita N, et al. Crystal structure of measles virus hemagglutinin provides insight into effective vaccines. Proc Natl Acad Sci U S A 2007; 104:19535-19540
14. Dorig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993;75:295-305. (Pubitemid 23320293)
15. NanicheD,Varior-KrishnanG,CervoniF,etal. Humanmembranecofactorprotein(CD46)actsasacellularreceptorformeaslesvirus. JVirol1993;67:6025-6032(Pubitemid23277513)
16. Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDwl 50) is a cellular receptor for measles virus. Nature 2000;406:893-898 (Pubitemid 30664265)
17. Yanagi Y, Takeda M, Ohno S. Measles virus: cellular receptors, tropism and pathogenesis. J Gen Virol 2006;87:2767-2779 (Pubitemid 44463885)
18. Erlenhofer C, Duprex WP, Rima BK, ter Meulen V, Schneider-Schaulies J. Analysis of receptor (CD46, CD 150) usage by measles virus. J Gen Virol 2002;83:1431-1436
19. Santiago C, Bjorling E, Stehle T, Casasnovas JM. Distinct kinetics for binding of the CD46 and SLAM receptors to overlapping sites in the measles virus hemagglutinin protein. J Biol Chem 2002; 277:32294-32301 (Pubitemid 34969046)
20. Olszewska W, Obeid OE, Steward MW Protection against measles virus-induced encephalitis by anti-mimotope antibodies: the role of antibody affinity. Virology 2000;272:98-105. (Pubitemid 30429433)
21. Phan TG, Paus D, Chan TD, et al. High affinity germinal center B cells are actively selected into the plasma cell compartment. J Exp Med 2006;203:2419-2424 (Pubitemid 44664611)
22. Polack FP, Hoffman SJ, Crujeiras G, Griffin DE. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med 2003;9:1209-1213 (Pubitemid 37173707)
23. Moss WJ, Monze M, Ryon JJ, Quinn TC, Griffin DE, Cutts F. Prospective study of measles in hospitalized, human immunodeficiency virus (HlV)-infected and HIV-uninfected children in Zambia. Clin Infect Dis 2002;35:189-196 (Pubitemid 34753905)
24. Ono N, Tatsuo H, Hidaka Y, Aoki T, Minagawa HY. Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDwl50) but not CD46 as a cellular receptor. J Virol 2001;75:4399-4401 (Pubitemid 32410152)
25. Cohen BJ, Audet S, Andrews N, Beeler J. Plaque reduction neutralization test for measles antibodies: description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine 2007; 26:59-66. (Pubitemid 50008088)
26. Nair N, Gans H, Lew-Yasukawa L, Long-Wagar AC, Arvin A, Griffin DE. Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis 2007; 196:1339-1345
27. Macdonald RA, Hosking CS, Jones CL. The measurement of relative antibody affinity by ELISA using thiocyanate elution. J Immunol Methods 1988;106:191-194 (Pubitemid 18054243)
28. Pullen GR, Fitzgerald MG, Hosking CS. Antibody avidity determination by ELISA using thiocyanate elution. J Immunol Methods 1986; 86:83-87
29. Beauverger P, Buckland R, Wild F. Establishment and characterisation of murine cells constitutively expressing the fusion, nucleoprotein and matrix proteins of measles virus. J Virol Methods 1993;44:199-210. (Pubitemid 23313384)
30. Hummel KB, Erdman DD, Heath J, Bellini WJ. Baculovirus expression of the nucleoprotein gene of measles virus and utility of the recombinant protein in diagnostic enzyme immunoassays. J Clin Microbiol 1992;30:2874-2880
31. van den HS, Gageldonk-Lafeber AB, Van Binnendijk RS, van Gageldonk PG, Berbers GA. Comparison of measles virus-specific antibody titres as measured by enzyme-linked immunosorbent assay and virus neutralisation assay. Vaccine 2003;21:4210-4214
32. Cohen BJ, Dobias D, Andrews N. Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination. Vaccine 2008; 26: 6392-6397
33. Cozine CL, Wolniak KL, Waldschmidt TJ. The primary germinal center response in mice. Curr Opin Immunol 2005; 17:298-302. (Pubitemid 40692665)
34. Dudley DD, Chaudhuri J, Bassing CH, Alt FW Mechanism and control of V(D)J recombination versus class switch recombination: similarities and differences. Adv Immunol 2005;86:43-112.
35. ScamurraRW,MillerDJ,DahlL,etal.ImpactofHIV- 1infectiononVH3generepertoireofnaivehumanBcells.JImmunol2000;164: 5482-5491(Pubitemid30305233)
36. WisnewskiA,CavaciniL,PosnerM.HumanantibodyvariableregiongeneusageinHIV- Iinfection.JAcquirImmuneDeficSyndrHumRetroviral1996;11:31-38(Pubitemid26020573)
37. PoliG,PantaleoG,FauciAS. Immunopathogenesisofhumanimmunodeficiencyvirusinfection.ClinInfectDis1993;17: S224-9.(Pubitemid23227136)
38. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9:235-245
39. Cagigi A, Nilsson A, De MA, Chiodi F. B cell immunopathology during HIV-I infection: lessons to learn for HIV-1 vaccine design. Vaccine 2008;26:3016-3025
40. Malaspina A, Moir S, Ho J, et al. Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc Natl Acad Sei USA 2006;103:2262-2267 (Pubitemid 43271658)
41. Moir S, Malaspina A, Pickeral OK, et al. Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med 2004;200:587-599 (Pubitemid 39258308)
42. De MA, Nilsson A, Titanji K, et al. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 2004; 103:2180-2186 (Pubitemid 38326236)
43. Titanji K, De MA, Cagigi A, et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 2006; 108:1580-1587 (Pubitemid 44316125)
44. Qiao X, He B, Chiu A, Knowles DM, Chadburn A, Cerutti A. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol 2006; 7: 302-310
45. TaruishiM,TerashimaK,DewanZ,etal. RoleoffolliculardendriticcellsintheearlyHIV-1infection: invitromodelwithoutspecificantibody.MicrobiolImmunol2004;48:693-702. (Pubitemid39264942)